For Immediate Release
Prodesse's Hexaplex® Selected for Use in Phase 3 Clinical Trial
WAUKESHA, WI (June 20, 2005) - Prodesse announced today that it recently signed an agreement with a global pharmaceutical firm for Prodesse to perform its Hexaplex assay as part of an FDA phase 3 clinical trial. Hexaplex will be used to determine efficacy of the preventative treatment. According to Karen Harrington, PhD, Clinical Laboratory Manager, "The selection of Prodesse’s Hexaplex for a primary clinical endpoint study is further testimony to the performance and quality of our Hexaplex assay. We have had a number of other large organizations use our products for their precise pathogen detection requirements, but this is the first time we have had to pass the rigorous audits associated with a phase 3 study."
About Prodesse
Prodesse is a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious disease applications. The company’s products are designed based on a combination of Prodesse’s patented technologies and other licensed technologies. Prodesse sells research use only kits worldwide, CE Marked in vitro diagnostic kits outside the US , FDA 510(k) cleared products worldwide and analyte specific reagents in the US . Analyte specific reagents can be used by CLIA certified laboratories to develop assays for detecting infectious organisms. The company’s products can be used on multiple nucleic acid extraction and PCR detection platforms. Prodesse also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com.
Press Contact:
Andy Shrago, Chief Marketing Officer
Prodesse, Inc.
Phone: (262) 446-0700
Email: ashrago@prodesse.com